10x Genomics (TXG) Revenue (2018 - 2026)

10x Genomics (TXG) has 9 years of Revenue data on file, last reported at $150.8 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 2.61% year-over-year to $150.8 million; the trailing twelve-month figure through Mar 2026 stood at $638.8 million (up 2.26% YoY), and the FY2025 full-year result was $642.8 million, up 5.25% from the prior year.
• Revenue retreated to $150.8 million in Q1 2026, from $166.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $184.0 million in Q4 2023 to a low of $114.5 million in Q1 2022.
• A 5-year average of $149.4 million and a median of $151.7 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue rose 28.1% in 2023 and decreased 10.3% in 2024, its largest moves.
• Tracing TXG's Revenue over 5 years: stood at $156.2 million in 2022, then increased by 17.76% to $184.0 million in 2023, then declined by 10.3% to $165.0 million in 2024, then grew by 0.61% to $166.0 million in 2025, then dropped by 9.15% to $150.8 million in 2026.
• Business Quant data shows TXG's Revenue at $150.8 million in Q1 2026, $166.0 million in Q4 2025, and $149.0 million in Q3 2025.